In November’s session we will be discussing the the regulatory issues with access to Medicines for Scleroderma in Australia.
Dr Andrew Pengilley is a Public Health Physician with 24 years experience working in various areas of public health within the Commonwealth and State and Territory Governments. For the past five years he has been a Principal Medical Advisor at the Therapeutic Goods Administration (TGA), where he works as the head of the premarket evaluation section dealing with vaccines and anti-infectives. Prior to this Dr Pengilley worked in the ACT and Victorian Health Departments in areas dealing with infectious disease control, as well as in health promotion policy.